Intellectual Property In India: Novartis Gleevec Patent Battle Will Go On Without Government Document Supporting “Evergreening” (Part 1 of 3)
This article was originally published in The Pink Sheet Daily
Executive Summary
In the first part of a three-part series on difficulties faced by drug manufacturers in patenting products in India, “The Pink Sheet” DAILY looks at the uphill battle Novartis faces in its lawsuit against the government to obtain a patent for a new formulation of Gleevec.
You may also be interested in...
Lost In Bureaucracy? Novartis Gleevec IP Case Held Up By Indian Legal System
Novartis is concerned that the changing intricacies of the Indian legal system will indefinitely delay its court case challenging the Indian Patent Office's denial of the Gleevec (imatinib) patent in the developing country
Lost In Bureaucracy? Novartis Gleevec IP Case Held Up By Indian Legal System
Patent case for new form of imatinib will now be reviewed by newly formed Intellectual Property Appellate Board.
Lost In Bureaucracy? Novartis Gleevec IP Case Held Up By Indian Legal System
Patent case for new form of imatinib will now be reviewed by newly formed Intellectual Property Appellate Board.